College of Pharmacy Faculty Research ​and Publications

Lecanemab-irmb (Leqembi™) for Treatment of Alzheimer’s Disease

Document Type

Article

Publication Title

The Senior Care Pharmacist

Publication Date

2-1-2024

Volume

39

Issue

2

First Page

75

Last Page

77

Abstract

Lecanemab-irmb (Leqembi™) is an amyloid beta-directed antibody indicated for the treatment of Alzheimer’s disease (AD). AD is an irreversible and progressive neurodegenerative disorder affecting more than 6.5 million Americans 65 years of age and older and it is projected to rise to 14 million by 2060. As the disease progresses, it deteriorates short-term memory and thinking skills and, eventually, the ability to perform simple tasks of daily living. The cost of care for AD patients in the United States is estimated at more than $183 billion every year.

Copyright held by

American Society of Consultant Pharmacists

Link to Full Text

Share

COinS